Pyrimethamine / sulfadoxine Pregnancy and Breastfeeding Warnings
Pyrimethamine / sulfadoxine is also known as: Fansidar
Pyrimethamine / sulfadoxine Pregnancy Warnings
Pyrimethamine-sulfadoxine was used as part of a study of 357 women in the first or second trimester of pregnancy living in an area of chloroquine-resistant malaria. Pyrimethamine-sulfadoxine treatment (three tablets once) followed by chloroquine prophylaxis was given to 117 women, and pyrimethamine-sulfadoxine treatment followed by a second treatment course at the beginning of the third trimester was given to 136 women. Scleral icterus was observed in five of 177 newborns examined. The most recent dose of pyrimethamine-sulfadoxine administered was 40 to 103 days prior to delivery. No other mention of adverse fetal outcome was made. One woman was treated with pyrimethamine 25 to 50 mg daily for central nervous system toxoplasmosis from the twenty-eighth week of gestation until birth. No adverse fetal outcome was reported. Another woman taking weekly chloroquine, dapsone, and pyrimethamine at the time of conception and for 45 days thereafter, gave birth to a stillborn infant with a severe defect of the abdominal and thoracic wall and a missing left arm.
Sulfadoxine-pyrimethamine has been assigned to pregnancy category C by the FDA. Sulfadoxine-pyrimethamine has been shown to be teratogenic in rats when given in weekly doses approximately 12 times the normal human dose. Women in endemic areas should be advised to use a reliable form of contraception and avoid becoming pregnant during prophylaxis and for three months after the last dose. Sulfadoxine-pyrimethamine should only be used during pregnancy if the benefit outweighs the risk to the fetus. Because pyrimethamine is a folate antagonist, folic acid supplementation should be given during pregnancy. Because sulfonamides compete with bilirubin for binding to serum albumin, free bilirubin levels rise in the presence of sulfonamides. Therefore, neonates are at risk of hyperbilirubinemia, jaundice, and kernicterus when sulfonamides are administered to the mother near term (prior to birth, the fetus is able to dispose of bilirubin via the placental circulation). Sulfadoxine-pyrimethamine prophylaxis is contraindicated at term.
Pyrimethamine / sulfadoxine Breastfeeding Warnings
Pyrimethamine is excreted into human milk. In three women treated with a combination of dapsone and pyrimethamine, the milk: serum ratio of pyrimethamine ranged from 0.46 to 0.66. The American Academy of Pediatrics considers pyrimethamine to be compatible with breast-feeding. Sulfonamides in general are excreted into human milk. For healthy, full-term neonates, sulfonamide excretion into breast milk does not pose a significant risk. Sulfonamides should be avoided if the infant being breast-fed is ill, premature, or has hyperbilirubinemia or glucose-6-phosphate dehydrogenase deficiency. The American Academy of Pediatrics considers some other sulfonamides compatible with breast-feeding of full-term healthy infants. The manufacturer states that sulfadoxine-pyrimethamine therapy is contraindicated during breast-feeding due to the risk of kernicterus from the excretion of sulfonamide into breast milk.
- pyrimethamine/sulfadoxine Consumer Information
- Pregnancy Support Group
- FDA Pregnancy Categories
- Medicine use during Pregnancy
- Medicine use while Breastfeeding
- Safe Medications during Breastfeeding
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.